Clinical Trials Browser

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04964934 2026-04-21

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT06930859 2026-04-20

ELEGANCE

Recruiting

2,766 enrolled

Breast

Breast Neoplasms

NCT07405801 2026-04-20

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT06726148 2026-04-17

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

280 enrolled

Breast

Breast Neoplasms

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07400523 2026-04-17

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

446 enrolled

Breast

Breast Neoplasms

NCT07085767 2026-04-16

OPERA-02

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

57 enrolled

Breast

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

Breast

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

86 enrolled

Breast

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

300 enrolled

Breast

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

255 enrolled

Breast

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 3 FDA

Breast

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Completed

2,424 enrolled

Breast

Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Recruiting

3,250 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

Clinical Trials

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

SERENA-6

ELEGANCE

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

OPERA-02

FAIM

Study of INCB123667 in Subjects With Advanced Solid Tumors

Adjuvant WIDER

Managed Access Programs for LEE011, Ribociclib

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Roll-over Study to Allow Continued Access to Ribociclib

SIE-3

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

NATALEE

PROSPERITY

CAROLEEN

IMPULSE

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer